Table 3.
PPVs for acute pancreatitis and primary malignancy
| Sample | Obtained medical records, n | Cases with insufficient information, n (%) | Confirmed casesa after medical record review, n | PPVsb of cases with sufficient information, % (95% CI) |
|---|---|---|---|---|
| Overall | ||||
| Acute pancreatitis | 145 | 16 (11.0) | 113 | 87.6 (80.8–92.2) |
| Primary malignancy (excluding non-melanoma skin cancer) | 141 | 15 (10.6) | 111 | 88.1 (81.3–92.7) |
| Denmark | ||||
| Acute pancreatitis | 42 | 2 (4.8) | 33 | 82.5 (68.1–91.3) |
| Primary malignancy (excluding non-melanoma skin cancer) | 50 | 4 (8.0) | 41 | 89.1 (77.0–95.3) |
| Norway | ||||
| Acute pancreatitis | 54 | 14 (25.9) | 37 | 92.5 (80.1–97.4) |
| Incident primary malignancy (excluding non-melanoma skin cancer) | 48 | 8 (16.7) | 38 | 95.0 (83.5–98.6) |
| Sweden | ||||
| Acute pancreatitis | 49 | 0 (0.0) | 43 | 87.8 (75.8–94.3) |
| Primary malignancy (excluding non-melanoma skin cancer) | 43 | 3 (7.0) | 32 | 80.0 (65.2–89.5) |
Notes:
a
Confirmed cases based on medical record review.
b
PPV is calculated as the number of confirmed cases after medical record review divided by the number of obtained medical charts with sufficient information.
Abbreviation: PPVs, positive predictive values.